BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis

Area of Science:

• Genetics and Oncology
• Cancer Susceptibility Genes

Background:

• BRCA1 and BRCA2 mutations significantly elevate lifetime risks for breast (up to 80%) and ovarian cancers (up to 40%).
• Distinct clinico-pathological features exist for BRCA1-related breast cancer, but are less defined for BRCA2.
• Morphologically, BRCA1/2-related ovarian cancers are indistinguishable from non-hereditary types, though microarray data suggest underlying differences.

Purpose of the Study:

• To review current knowledge on BRCA1/2 gene mutations in breast and ovarian cancers.
• To highlight the prognostic differences and chemotherapy sensitivities associated with BRCA1/2 mutations.
• To identify gaps in understanding regarding chemotherapy response in BRCA1/2 mutation carriers, particularly for breast cancer.

Main Methods:

• Review of clinico-pathological, prognostic, and in vitro chemo-sensitivity studies.
• Analysis of survival data for ovarian cancer patients with BRCA1/2 mutations versus non-carriers.
• Examination of existing literature on chemotherapy response in BRCA1/2 mutation carriers for breast cancer.

Main Results:

• BRCA1/2 mutations confer substantial lifetime cancer risks.
• BRCA1/2-related ovarian cancer patients generally have improved survival, especially with platinum-based therapy, due to potential sensitivity to DNA-damaging agents.
• Breast cancer in BRCA1 carriers may have similar or worse outcomes than in BRCA2 or non-carriers; chemotherapy response differences are largely unknown.

Conclusions:

• BRCA1/2 mutations are key genetic factors in hereditary breast and ovarian cancers.
• Ovarian cancer patients with BRCA1/2 mutations benefit from platinum-based therapies.
• Prospective studies and randomized controlled trials are crucial to elucidate chemotherapy responses in BRCA1/2 mutation carriers for breast cancer.